Blood pressure drug recalled due to risk of patient harm

One lot of generic propranolol hydrochloride extended-release capsules has been recalled due to a potential risk metal contamination. New Jersey-based Breckenridge Pharmaceutical issued a statement about the recall, highlighting the risks of consuming these capsules.

Propranolol hydrochloride is a beta-blocker often prescribed to treat hypertension or arrhythmias. It has also been known to reduce migraine symptoms due to its effect on blood vessels in the brain. Propranolol hydrochloride has been sold under various brand names, but this specific recall is for one lot of a generic version of the drug.

“Use of product from the affected lot could potentially cause lacerations of soft tissues in the oral cavity, esophagus, stomach or intestine,” the company explained. “The affected lot shared intermediate material suspected to be the source of metal contamination identified in a separate lot that was not released to market.”

Breckenridge Pharmaceutical emphasized that no adverse events have been linked to this issue. However, due to the risk, the company is urging patients to “immediately stop” taking the capsules and reach out to a healthcare provider for “medical advice and replacement instructions.” Patients have also been asked to return any unused medications to where they originally obtained them. 

Subscribe to Cardiovascular Business News

“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product,” the company added. “Wholesalers, pharmacies, and other retail entities should check inventory for the recalled lot, quarantine any affected product, and not distribute or dispense the affected product. Entities that further distributed the product should notify their sub-accounts to the retail level.”

The lot number included in this recall is PK25110035. These capsules were distributed from October to November 2026. They are set to expire in May 2029.

It is unclear at this time if the U.S. Food and Drug Administration (FDA) has ruled this a Class I or Class II recall. Breckenridge Pharmaceutical did note that the agency is aware of the issue. 

If any clinicians have an adverse event to report, they should contact the FDA.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Subscribe to Cardiovascular Business News

Subscribe to Cardiovascular Business News